mozavaptan has been researched along with lixivaptan in 9 studies
| Studies (mozavaptan) | Trials (mozavaptan) | Recent Studies (post-2010) (mozavaptan) | Studies (lixivaptan) | Trials (lixivaptan) | Recent Studies (post-2010) (lixivaptan) |
|---|---|---|---|---|---|
| 165 | 8 | 24 | 80 | 10 | 26 |
| Protein | Taxonomy | mozavaptan (IC50) | lixivaptan (IC50) |
|---|---|---|---|
| Vasopressin V2 receptor | Homo sapiens (human) | 0.0172 | |
| Oxytocin receptor | Homo sapiens (human) | 0.519 | |
| Vasopressin V1a receptor | Rattus norvegicus (Norway rat) | 0.293 | |
| Vasopressin V1a receptor | Homo sapiens (human) | 0.1805 | |
| Vasopressin V2 receptor | Rattus norvegicus (Norway rat) | 0.0018 | |
| Sigma non-opioid intracellular receptor 1 | Homo sapiens (human) | 0.001 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (11.11) | 18.2507 |
| 2000's | 5 (55.56) | 29.6817 |
| 2010's | 3 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Albright, JD; Bailey, T; Chan, PS; Coupet, J; Delos Santos, EG; Dusza, JP; Mazandarani, H; Reich, MF; Ru, X; Sum, FW; Venkatesan, AM | 1 |
| Double-Cazanave, E; Garcia, C; Guillon, G; Maffrand, JP; Pascal, M; Raufaste, D; Serradeil-Le Gal, C | 1 |
| Gross, P; Palm, C | 1 |
| Ferguson, JW; Hayes, PC; Newby, DE; Therapondos, G | 1 |
| Chen, RH; Demarest, KT; Ericson, E; Gunnet, J; Look, R; Murray, WV; Rybczynski, PJ; Urbanski, MJ; Zhang, X | 1 |
| Gross, P; Herbrig, K; Palm, C; Pistrosch, F | 1 |
| Villabona, C | 1 |
| Dabrowska, MD; Krysiak, R; Okopień, B | 1 |
| Iwao, H; Izumi, Y; Miura, K | 1 |
6 review(s) available for mozavaptan and lixivaptan
| Article | Year |
|---|---|
The treatment of hyponatraemia using vasopressin antagonists.
Topics: Antidiuretic Hormone Receptor Antagonists; Azepines; Benzamides; Benzazepines; Humans; Hyponatremia; Morpholines; Pyrroles; Receptors, Vasopressin; Spiro Compounds; Vasopressins | 2000 |
Therapeutic role of vasopressin receptor antagonism in patients with liver cirrhosis.
Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Azepines; Benzamides; Benzazepines; Controlled Clinical Trials as Topic; Diuretics; Heart Failure; Homeostasis; Humans; Inappropriate ADH Syndrome; Liver Cirrhosis; Models, Animal; Morpholines; Piperidines; Pyrroles; Quinolones; Rats; Spiro Compounds; Vasopressins | 2003 |
Vasopressin antagonists as aquaretic agents for the treatment of hyponatremia.
Topics: Antidiuretic Hormone Receptor Antagonists; Azepines; Benzamides; Benzazepines; Humans; Hyponatremia; Inappropriate ADH Syndrome; Morpholines; Pyrroles; Randomized Controlled Trials as Topic; Spiro Compounds; Tolvaptan; Vasopressins | 2006 |
[Vasopressin receptor antagonists: the vaptans].
Topics: Adult; Antidiuretic Hormone Receptor Antagonists; Aquaporin 2; Benzamides; Benzazepines; Calcium Signaling; Clinical Trials as Topic; Cyclic AMP; Double-Blind Method; Drug Therapy, Combination; Heart Failure; Humans; Hyponatremia; Inappropriate ADH Syndrome; Kidney Tubules, Collecting; Liver Cirrhosis; Morpholines; Multicenter Studies as Topic; Neoplasms; Pituitary Gland, Anterior; Pyrroles; Randomized Controlled Trials as Topic; Receptors, Vasopressin; Second Messenger Systems; Spiro Compounds; Tolvaptan; Vasopressins | 2010 |
[Hyponatremic hypervolemia in heart failure--the hot spot for vasopressin receptor antagonists?].
Topics: Antidiuretic Hormone Receptor Antagonists; Benzamides; Benzazepines; Diuretics; Heart Failure; Humans; Hyponatremia; Hypovolemia; Morpholines; Pyrroles; Spiro Compounds; Tolvaptan | 2012 |
Therapeutic potential of vasopressin-receptor antagonists in heart failure.
Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Benzamides; Benzazepines; Body Water; Clinical Trials as Topic; Disease Models, Animal; Heart Failure; Homeostasis; Humans; Hyponatremia; Morpholines; Pyrroles; Receptors, Vasopressin; Spiro Compounds; Tolvaptan; Ventricular Remodeling | 2014 |
1 trial(s) available for mozavaptan and lixivaptan
| Article | Year |
|---|---|
5-Fluoro-2-methyl-N-[4-(5H-pyrrolo[2,1-c]-[1, 4]benzodiazepin-10(11H)-ylcarbonyl)-3-chlorophenyl]benzamide (VPA-985): an orally active arginine vasopressin antagonist with selectivity for V2 receptors.
Topics: Administration, Oral; Animals; Arginine Vasopressin; Azepines; Benzamides; Blood Platelets; Body Water; Cell Line; Cell Membrane; Dogs; Fibroblasts; Humans; Kidney; Liver; Osmolar Concentration; Pyrroles; Rats; Receptors, Vasopressin; Sodium; Structure-Activity Relationship; Urine | 1998 |
2 other study(ies) available for mozavaptan and lixivaptan
| Article | Year |
|---|---|
Binding properties of a selective tritiated vasopressin V2 receptor antagonist, [H]-SR 121463.
Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Binding, Competitive; Cattle; CHO Cells; Cricetinae; Dogs; Haplorhini; Homeostasis; Humans; Kidney; Kinetics; Morpholines; Rabbits; Radioligand Assay; Rats; Spiro Compounds; Swine; Tritium; Vasopressins; Water-Electrolyte Balance | 2000 |
2,5-disubstituted 3,4-dihydro-2H-benzo[b][1,4]thiazepines as potent and selective V2 arginine vasopressin receptor antagonists.
Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Azepines; Benzamides; Benzazepines; Dibenzothiazepines; Diuresis; Drug Design; Kinetics; Male; Pyrroles; Rats; Structure-Activity Relationship | 2003 |